Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 12Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms, Castration-Resistant 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumours 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

radium Ra 223 dichloride 2enzalutamide 2darolutamide 1avelumab 1abiraterone 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metastatic Castration-resistant Prostate Cancer × abiraterone × Clear all
NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Tulane University

Phase 2 Terminated
8 enrolled 7 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡